AI Generated Image
SC: Upstate clinic leads research on promising Alzheimer’s drug
WYFF • • health
Key Points:
- Tribe Clinical Research in Greenville, South Carolina, is leading research on Remternetug, a drug targeting an abnormal protein linked to Alzheimer's disease, aiming to slow disease progression.
- CEO Jennifer Lehman, personally connected to Alzheimer's through her family, describes the drug as working to remove protein "clogs" that contribute to the disease, unlike current treatments that only alleviate symptoms.
- The medication is in its final phase before FDA approval and has already been administered to at least 40 patients in the Upstate region participating in the study.
- Although the current research registry for Remternetug is closed to new participants, Tribe Clinical Research is seeking volunteers for other ongoing studies related to Alzheimer's disease.
